Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR inhibition with Cetuximab in pulmonary arterial hypertension associated with systemic sclerosis
2006-002081-19Phase 2Active
- Sponsor
- VU University Medical Centre
- Start
- Jul 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of cetuximab in pulmonary arterial hypertension (PAH) and systemic sclerosis (SSc), sponsored by VU University Medical Centre. Primary endpoint: Safety. Started Jul 2006; status: active.
02
Drugs
cetuximab
03
Conditions
pulmonary arterial hypertension (PAH)systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2006-002081-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002081-19.